biologic

Awiqli

insulin icodec-abae

Loss of exclusivityMarch 2038projected — 12-year biologic exclusivity estimate
CompanyNovo Nordisk Inc.

Drug detail

Brand nameAwiqli
Active ingredientinsulin icodec-abae
Strength2,100UNITS/3ML (700UNITS/ML)
Dosage formInjection
RouteSubcutaneous
ModalityBiologic
FDA approvalMarch 2026
Marketing statusRx

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Awiqli patent cliff — loss of exclusivity March 2038 | CliffBio